About the Authors

Erick H. Turner
Department of Psychiatry, Oregon Health & Science University, Portland, Oregon, United States of America

Erick H. Turner
Department of Pharmacology, Oregon Health & Science University, Portland, Oregon, United States of America

Erick H. Turner
Center for Ethics in Health Care, Oregon Health & Science University, Portland, Oregon, United States of America

Erick H. Turner
Behavioral Health and Neurosciences Division, Portland Veterans Affairs Medical Center, Portland, Oregon, United States of America

Daniel Knoepflmacher, Lee Shapley
School of Medicine, Oregon Health & Science University, Portland, Oregon, United States of America

Corresponding Author

turnere@ohsu.edu

Competing Interests

From 1998 to 2001, ET served as a medical reviewer at the US Food and Drug Administration (FDA). Subsequently, but ending in 2005, ET provided outside consulting to Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline. From 2004 to 2005, ET was on the speaker's bureaus of Eli Lilly, AstraZeneca, and Bristol-Myers Squibb. LS is Scorecard Director for the AMSA Pharmfree Scorecard, and a fourth year medical student at Oregon Health & Science University (OHSU). DK is also a fourth year medical student at OHSU and has no competing interests to report.

Author Contributions

Conceived and designed the experiments: ET. Performed the experiments: ET DK LS. Analyzed the data: ET. Contributed reagents/materials/analysis tools: ET. Wrote the first draft: ET. Wrote the paper: ET DK LS. ICMJE criteria for authorship read and met: ET DK LS. Agree with the manuscript's results and conclusions: ET DK LS.